Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
Holding RXST?
Track your performance easily
RXST Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$27.07 - $66.54
Previous Close$45.05
Volume668.98K
Average Volume (3M)478.16K
Market Cap
$1.82B
Enterprise Value$1.58B
Total Cash (Recent Filing)$237.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Mar 11, 2025EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding40,304,465
10 Day Avg. Volume989,918
30 Day Avg. Volume478,164
Standard Deviation0.15
R-Squared0.15
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)6.55
Price to Sales (P/S)13.87
Price to Cash Flow (P/CF)684.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.30
Enterprise Value/Gross Profit29.36
Enterprise Value/Ebitda-93.65
Forecast
1Y Price Target
$63.86Price Target Upside41.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
RxSight News
PremiumCompany Announcements
RxSight, Inc. Reports Strong Q3 Financial Results
Ownership Overview
4.89% Insiders
18.63% Mutual Funds
36.30% Other Institutional Investors
25.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $27.07 and its highest was $66.54 in the past 12 months.
What is RxSight’s market cap?
Currently, no data Available
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is Mar 11, 2025 which is in 110 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on Nov 07, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.086.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -$0.17.
How many shares outstanding does RxSight have?
RxSight has 40,304,466 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -5.585%.
Which hedge fund is a major shareholder of RxSight?
Among the largest hedge funds holding RxSight’s share is RA Capital Management. It holds RxSight’s shares valued at 222M.
---
RxSight Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.86 (41.75% Upside)
$63.86 (41.75% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 83%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 719.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 15.1%
Last 30 Days ▲ 15.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
63.99%
12-Months-Change
Fundamentals
Return on Equity
-13.99%
Trailing 12-Months
Asset Growth
70.73%
Trailing 12-Months
Company Description
RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
---
RXST Earnings Call
Q3 2024
0:00 / 0:00
---
RXST Stock 12 Month Forecast
Average Price Target
$63.86
▲(41.75% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Akero Therapeutics
―
ALX Oncology Holdings
―
Kiniksa Pharmaceuticals
―
Best Analysts Covering RXST
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+62.53%
reiterated a buy rating 4 months ago
Copying Robbie Marcus's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +62.53% per trade.
---